Latest Insider Transactions at F Star Therapeutics, Inc. (FSTX)
This section provides a real-time view of insider transactions for F Star Therapeutics, Inc. (FSTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of F-star Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of F-star Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 08
2023
|
Eliot Forster PRESIDENT AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
73,959
-100.0%
|
$517,713
$7.12 P/Share
|
|
Mar 08
2023
|
Eliot Forster PRESIDENT AND CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
347,578
-82.45%
|
$2,433,046
$7.12 P/Share
|
|
Mar 08
2023
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,019
-100.0%
|
$175,133
$7.12 P/Share
|
|
Mar 08
2023
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
29,236
-53.89%
|
$204,652
$7.12 P/Share
|
|
Mar 08
2023
|
Geoffrey Race Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,937
-100.0%
|
$27,559
$7.12 P/Share
|
|
Mar 08
2023
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,375
-100.0%
|
$65,625
$7.12 P/Share
|
|
Mar 08
2023
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
105,088
-91.81%
|
$735,616
$7.12 P/Share
|
|
Mar 08
2023
|
Todd C Brady Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,004
-100.0%
|
$105,028
$7.12 P/Share
|
|
Mar 08
2023
|
Darlene M Deptula Hicks Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,539
-100.0%
|
$178,773
$7.12 P/Share
|
|
Mar 08
2023
|
Darlene M Deptula Hicks Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,898
-54.75%
|
$216,286
$7.12 P/Share
|
|
Mar 08
2023
|
David Arkowitz Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,386
-100.0%
|
$58,702
$7.12 P/Share
|
|
Mar 08
2023
|
Edward Benz Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,385
-100.0%
|
$30,695
$7.12 P/Share
|
|
Mar 08
2023
|
Nessan Bermingham Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,328
-100.0%
|
$44,296
$7.12 P/Share
|
|
Mar 08
2023
|
Nessan Bermingham Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
97,547
-93.91%
|
$682,829
$7.12 P/Share
|
|
Jul 29
2022
|
Geoffrey Race Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,937
+50.0%
|
$0
$0.11 P/Share
|
|
Jul 29
2022
|
Eliot Forster PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
260,977
+38.24%
|
$0
$0.11 P/Share
|
|
Jul 29
2022
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
76,619
+40.1%
|
$0
$0.11 P/Share
|
|
Nov 02
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
64
-0.06%
|
$384
$6.83 P/Share
|
|
Oct 04
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
64
-0.12%
|
$448
$7.23 P/Share
|
|
Jul 02
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,054
-1.9%
|
$8,432
$8.43 P/Share
|
|
Feb 01
2021
|
Darlene M Deptula Hicks Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+34.71%
|
-
|
|
Feb 01
2021
|
Edward Benz Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,385
+50.0%
|
-
|
|
Feb 01
2021
|
Nessan Bermingham Director |
BUY
Grant, award, or other acquisition
|
Direct |
87,000
+45.58%
|
-
|
|
Feb 01
2021
|
Louis Kayitalire CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+34.35%
|
-
|
|
Feb 01
2021
|
Eliot Forster PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
142,000
+46.93%
|
-
|
|
Feb 01
2021
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+32.23%
|
-
|
|
Nov 20
2020
|
Neil Brewis CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
19,844
+50.0%
|
-
|
|
Nov 20
2020
|
Eliot Forster PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
18,560
+50.0%
|
-
|
|
Nov 20
2020
|
Radhakrishnan P. Iyer Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
175
-0.14%
|
$700
$4.76 P/Share
|
|
Nov 20
2020
|
Lori Firmani VP of Finance and Treasurer |
SELL
Open market or private sale
|
Direct |
175
-0.97%
|
$700
$4.76 P/Share
|
|
Nov 20
2020
|
Martin J Driscoll President and CEO |
SELL
Open market or private sale
|
Direct |
175
-0.37%
|
$700
$4.76 P/Share
|
|
Nov 20
2020
|
Garrett Winslow General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
175
-0.93%
|
$700
$4.76 P/Share
|
|
Nov 19
2020
|
Radhakrishnan P. Iyer Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+9.07%
|
-
|
|
Nov 19
2020
|
Radhakrishnan P. Iyer Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.24%
|
-
|
|
Nov 19
2020
|
Lori Firmani VP of Finance and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+40.93%
|
-
|
|
Nov 19
2020
|
Lori Firmani VP of Finance and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+40.36%
|
-
|
|
Nov 19
2020
|
Martin J Driscoll President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+23.96%
|
-
|
|
Nov 19
2020
|
Martin J Driscoll President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.47%
|
-
|
|
Nov 19
2020
|
Garrett Winslow General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+40.0%
|
-
|
|
Nov 19
2020
|
Garrett Winslow General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
-
|
|
Sep 30
2020
|
Timothy P Clackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,422
+15.73%
|
-
|
|
Sep 30
2020
|
Todd C Brady Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,235
+13.34%
|
-
|